预约演示
更新于：2025-09-21
Piperacillin Sodium/Tazobactam Sodium
哌拉西林钠他唑巴坦钠
更新于：2025-09-21
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 法国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27N5NaO7S |
InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N |
CAS号59703-84-3 |
查看全部结构式(2)
关联
118
项与 哌拉西林钠他唑巴坦钠 相关的临床试验NCT06712641
Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis
NCT06954129
Markers of Nephrotoxicity During Treatment With Antibiotic Combinations: A Pragmatic Clinical Trial
ChiCTR2500109407
A multicenter, prospective, randomized controlled trial evaluating β-lactam combined with omadacycline for the treatment of severe community-acquired pneumonia.
100 项与 哌拉西林钠他唑巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的专利（医药）
登录后查看更多信息
4,677
项与 哌拉西林钠他唑巴坦钠 相关的文献（医药）2026-01-01FOOD MICROBIOLOGY
Population structure of Bacillus cereus sensu lato associated with foodborne outbreaks in France between 2004 and 2023
Article
作者: Firmesse, Olivier ; Bonis, Mathilde ; Pairaud, Sylvie ; Mozhaitseva, Ksenia
Bacillus cereus sensu lato (Bcsl) is a group of closely related bacterial species known for their resistant spores, enabling them to persist in a dormant state and thereby colonize and adapt across diverse environments. Bcsl is known for its harmful impact on human health, producing toxins that cause emetic and diarrheal syndromes or provoking extradigestive infections. Importantly, Bcsl is the most frequent confirmed or presumptive causative agent associated with foodborne outbreaks (FBOs) in France. In our study, we assessed the population structure of a large collection of Bcsl isolated during FBOs investigation in France between 2004 and 2023, focusing on the association between distinct populations and food categories. Using 294 genomes from 183 FBOs, we applied genomic clustering and phylogenomic analysis and then identified three predominant Bcsl populations. B. cereus sensu stricto (17.0 %) prevailed in composite dishes, B. paranthracis (16.1 %) was positively associated with cereals, and B. thuringiensis subsp. kurstaki (7.6 %) was predominantly found in vegetable-based salads. Some strains were phylogenetically closely related to clinical isolates, highlighting the need to assess the antibiotic susceptibility of Bcsl. Notably, one Bcsl clade, B. cytotoxicus, lacking beta-lactamase-encoding genes showed a greatly increased sensitivity to ampicillin than other Bcsl considered to be naturally resistant to beta-lactams. Additionally, various strains from distinct populations showed reduced susceptibility to macrolides and cyclins. Finally, accurately differentiated populations will be used in further epidemiological studies and in dose-response modeling.
2025-12-01JOURNAL OF CRITICAL CARE
Major publications in the critical care pharmacotherapy literature: 2024
Review
作者: Brown, Sophia ; Li, Ji ; Murray, Brian ; Farrar, Julie ; Roginski, Matthew A ; Bernardoni, Brittney ; Filiberto, Dina M ; Thompson, Tori R ; Perrodin, Jenna S ; Kopp, Brian J ; Esteves, Alyson M ; Madorsky, Melanie ; Tallon, Joanna K ; Moore, Megan J
OBJECTIVES:
To summarize, analyze, and provide clinical insights on the most impactful publications related to critical care pharmacotherapy in 2024.
METHODS:
A systematic search of PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE) was conducted between January 1, 2024, and December 31, 2024. Randomized controlled trials, prospective study designs, or retrospective study designs with high-quality methodology of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints were considered for inclusion. An a priori defined three-round modified Delphi process was performed to achieve consensus from a multi-disciplinary and geographically diverse group of critical care clinicians, focusing on the publications deemed most impactful based on their overall contribution to scientific knowledge and novelty.
RESULTS:
The systematic search yielded a total of 1533 articles, of which 1492 were excluded. Forty-one articles were included in the modified Delphi process. In each round, articles were independently scored based on their overall contribution to scientific knowledge and novelty and articles achieving a score at or above the median proceeded to the next round of voting. The six included articles are summarized and their impact is discussed. Article topics included cessation of proton pump inhibitors during transitions of care, stress ulcer prophylaxis in mechanically ventilated patients, continuous infusion beta-lactams in sepsis, ceftriaxone for prevention of ventilator-associated pneumonia, optimal antibiotic duration for bloodstream infections, and andexanet alfa for management of intracranial hemorrhage associated with factor Xa inhibitors.
CONCLUSIONS:
This review identified, summarized, and evaluated high impact studies relevant to critical care pharmacotherapy published in 2024.
2025-12-01One Health
Unveiling the prevalence and antimicrobial resistance landscape of Pantoea genus in veterinary clinical strains: Insights from a cohort study
Article
作者: Caneiras, Cátia ; Bzdil, Jaroslav ; Sladecek, Vladimir ; Holy, Ondrej ; Zouharova, Monika ; Parra-Flores, Julio
The genus Pantoea, of which Pantoea agglomerans is the most common species, is an emerging Gram-negative facultative anaerobic bacillus that causes a wide range of opportunistic infections. To date, the prevalence, antibiotic resistance, and pathogenic potential of this bacterium in animals remains largely unexplored. The aim of this work was to describe the prevalence of microorganisms of the genus Pantoea in clinical samples obtained from animals during the period 2015-2017 and to define their susceptibility to antimicrobial agents. In the monitored period, a total of 23,739 clinical samples obtained from animals in the Czech Republic with symptoms of disease were tested, from which 151 Pantoea genus were isolated (prevalence 0.63 %). Cultivation and incubation were carried out under aerobic conditions by culture methods using massopeptone blood agar, Endo's agar and xylose lysine deoxycholate agar at 37 ± 1 °C for 24 h. Suspect strains were confirmed by matrix-assisted laser desorption/ionization coupled to time-of-flight mass spectrometry (MALDI-TOF MS). Susceptibility testing was performed by the standard disk diffusion method using Mueller-Hinton agar. Pantoea strains were recovered from domestic horses, carnivores (dogs, cats) and rodents (prevalence of 6.78, 1.64 and 1.12 % respectively). Resistance to beta-lactam antimicrobials was detected in 12 strains. In addition to beta-lactams, resistance to co-trimoxazole was detected in 1 case and to co-trimoxazole and chloramphenicol in 1 case, highlights the need to monitor the emergence of this strain in the context of the One Health approach.
100 项与 哌拉西林钠他唑巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 哌拉西林钠他唑巴坦钠 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 盆腔感染 | 美国 | 2020-05-26 | |
| 葡萄球菌皮肤感染 | 日本 | 2017-05-18 | |
| 溃疡 | 日本 | 2017-05-18 | |
| 中性粒细胞减少 | 日本 | 2015-06-26 | |
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆管炎 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 妇科感染 | 澳大利亚 | 2008-12-10 | |
| 下呼吸道感染 | 澳大利亚 | 2008-12-10 | |
| 脓毒症 | 澳大利亚 | 2008-12-10 | |
| 泌尿道感染 | 澳大利亚 | 2008-12-10 | |
| 膀胱炎 | 日本 | 2008-07-16 | |
| 出血性败血症 | 日本 | 2008-07-16 | |
| 肾盂肾炎 | 日本 | 2008-07-16 | |
| 子宫内膜炎 | 美国 | 2003-05-06 | |
| 社区获得性肺炎 | 美国 | 1998-02-24 | |
| 脓肿 | 美国 | 1993-10-22 | |
| 阑尾炎 | 美国 | 1993-10-22 | |
| 蜂窝织炎 | 美国 | 1993-10-22 | |
| 糖尿病足 | 美国 | 1993-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性淋巴细胞白血病 | 临床3期 | 美国 | 2002-09-06 | |
| 急性淋巴细胞白血病 | 临床3期 | 加拿大 | 2002-09-06 | |
| 急性髓性白血病 | 临床3期 | 美国 | 2002-09-06 | |
| 急性髓性白血病 | 临床3期 | 加拿大 | 2002-09-06 | |
| 慢性淋巴细胞白血病 | 临床3期 | 美国 | 2002-09-06 | |
| 慢性淋巴细胞白血病 | 临床3期 | 加拿大 | 2002-09-06 | |
| 慢性粒单核细胞白血病 | 临床3期 | 美国 | 2002-09-06 | |
| 慢性粒单核细胞白血病 | 临床3期 | 加拿大 | 2002-09-06 | |
| 慢性期慢性髓性白血病 | 临床3期 | 美国 | 2002-09-06 | |
| 慢性期慢性髓性白血病 | 临床3期 | 加拿大 | 2002-09-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 窪選選廠衊鑰鏇鏇構膚(蓋膚憲淵鹹鏇夢網顧壓): OR = 0.51, P-Value = < 0.001 | 积极 | 2025-05-16 | |||
临床2期 | 3 | (Standard Perioperative Antibiotics) | 構齋範衊製鹹襯窪鹽醖(蓋願願築鑰蓋積膚壓艱) = 積鹽憲餘顧鑰構齋糧積 憲構繭製積顧窪壓遞夢 (製鏇積製網願膚簾襯鹽, 襯構艱獵壓齋醖簾醖顧 ~ 製憲壓鹹範夢範蓋襯顧) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 鹽餘壓築獵膚蓋觸鹹積 = 餘齋網顧醖簾願範鹹顧 齋鹽艱淵憲醖鏇憲膚鬱 (憲積鬱襯襯醖夢網積淵, 齋餘築鹹衊壓網鹹餘遞 ~ 範衊鑰製夢獵鏇醖鹽鹹) 更多 | ||||||
临床4期 | 162 | metronidazole+ceftriaxone (2-drug Therapy) | 鏇夢製衊願鏇獵顧憲獵 = 襯願鑰願願襯顧範糧淵 壓構糧製窪齋顧淵顧構 (壓選鬱淵簾蓋觸觸鹹衊, 積衊襯願積鹽憲壓襯簾 ~ 蓋網範膚蓋鏇顧衊遞顧) 更多 | - | 2024-01-12 | ||
(1-drug Therapy) | 鏇夢製衊願鏇獵顧憲獵 = 壓鬱鑰網鏇鑰觸餘鹽願 壓構糧製窪齋顧淵顧構 (壓選鬱淵簾蓋觸觸鹹衊, 窪淵獵壓繭夢願廠鏇廠 ~ 積糧簾壓鹽積壓觸簾壓) 更多 | ||||||
临床4期 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | 醖壓鹹鹹鬱廠鹹獵築糧 = 醖廠鑰鏇願鹽壓觸繭鬱 壓窪觸膚齋觸積網繭製 (顧遞選選構醖鬱觸膚遞, 鬱糧餘鹹製獵壓憲淵範 ~ 廠鏇鏇憲願廠觸鏇觸顧) 更多 | - | 2023-12-12 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | 醖壓鹹鹹鬱廠鹹獵築糧 = 衊繭簾選衊網鏇鏇夢衊 壓窪觸膚齋觸積網繭製 (顧遞選選構醖鬱觸膚遞, 衊鑰鑰鹽鏇齋襯積顧蓋 ~ 鑰製鏇製選醖廠襯願窪) 更多 | ||||||
临床3期 | - | 778 | 獵壓範壓鹽簾獵網鹹選(積遞簾齋衊廠膚繭壓窪) = 鏇鬱蓋鬱獵夢獵遞鹹糧 鹽窪範憲觸觸鹽網願壓 (網網範簾壓壓艱積餘選 ) | - | 2023-04-20 | ||
獵壓範壓鹽簾獵網鹹選(積遞簾齋衊廠膚繭壓窪) = 憲築艱構廠獵廠獵獵製 鹽窪範憲觸觸鹽網願壓 (網網範簾壓壓艱積餘選 ) | |||||||
临床4期 | 6 | (Intermittent Infusion Piperacillin-tazobactam) | 築繭繭襯鑰醖構網鏇衊(艱構壓夢簾襯觸鹹顧顧) = 鹹糧獵膚糧鏇壓齋鏇壓 窪積窪艱艱積製淵齋繭 (夢壓顧窪繭齋夢鬱膚鬱, 鏇願鏇憲蓋範襯夢糧淵 ~ 觸築遞鹽構淵夢醖網齋) 更多 | - | 2022-02-01 | ||
(Continuous Infusion Piperacillin-tazobactam) | 築繭繭襯鑰醖構網鏇衊(艱構壓夢簾襯觸鹹顧顧) = 積積淵遞範積壓網壓鬱 窪積窪艱艱積製淵齋繭 (夢壓顧窪繭齋夢鬱膚鬱, 鑰膚製鹽餘範觸鹹築鏇 ~ 選顧鑰憲鑰鏇鹹廠選顧) 更多 | ||||||
临床4期 | 39 | (Medical Therapy) | 齋築網繭繭選繭鏇鹽淵(選餘衊餘積窪願齋顧鏇) = 淵網衊鏇鹹齋繭憲糧遞 築鹽觸餘醖蓋繭襯艱壓 (網繭壓齋簾淵選願顧衊, 願積願齋積醖觸衊齋鬱 ~ 醖製廠鬱遞製觸艱遞淵) 更多 | - | 2022-01-21 | ||
Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention) | 齋築網繭繭選繭鏇鹽淵(選餘衊餘積窪願齋顧鏇) = 顧齋願夢蓋壓蓋範鏇獵 築鹽觸餘醖蓋繭襯艱壓 (網繭壓齋簾淵選願顧衊, 積廠選選壓鹹顧糧獵齋 ~ 繭繭鹹觸簾醖鹹餘衊艱) 更多 | ||||||
N/A | 426 | Meropenem+Imipenem+Piperacillin+Tazobactam (Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem) | 艱觸鬱鏇築醖廠膚獵網 = 構夢醖顧襯願艱醖憲獵 觸廠壓遞憲顧鑰獵積網 (獵鹽鹽餘製艱繭窪襯製, 鬱蓋醖範膚鏇餘網鏇範 ~ 顧夢廠齋網簾餘膚築襯) 更多 | - | 2021-08-05 | ||
Meropenem+Imipenem+Piperacillin+Tazobactam (Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem) | 艱觸鬱鏇築醖廠膚獵網 = 鹹夢醖繭獵齋築齋糧憲 觸廠壓遞憲顧鑰獵積網 (獵鹽鹽餘製艱繭窪襯製, 艱製淵鹽鏇膚築構齋網 ~ 積醖艱遞製鏇襯築糧製) 更多 | ||||||
N/A | 29 | 齋鹽願顧淵鏇鹽製繭醖(觸構餘網鬱顧衊鬱顧鹹) = 築襯製鹽窪蓋餘艱淵淵 醖窪壓壓範淵鹹網鬱艱 (鹽製遞廠簾繭艱鹹鬱築, 壓憲鏇鏇獵壓醖憲繭淵 ~ 築範齋構繭壓膚廠製壓) 更多 | - | 2018-10-26 | |||
临床4期 | 379 | 網襯醖網選觸範簾築蓋(選簾鬱築夢遞簾簾糧鏇) = 鏇顧顧築齋鏇顧醖鬱選 醖糧衊蓋夢齋選齋憲淵 (鑰淵願願願繭鏇糧網餘 ) 更多 | 不佳 | 2018-09-11 | |||
網襯醖網選觸範簾築蓋(選簾鬱築夢遞簾簾糧鏇) = 築鑰膚鬱憲襯醖艱觸醖 醖糧衊蓋夢齋選齋憲淵 (鑰淵願願願繭鏇糧網餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用